Vernalis plc (LON:VER) issued its quarterly earnings data on Tuesday. The company reported GBX (4.10) (($0.05)) EPS for the quarter, missing the Zacks’ consensus estimate of GBX (0.04) ($0.00) by GBX (4.06) (($0.05)), Digital Look Earnings reports. The business had revenue of GBX 207.90 billion during the quarter. Vernalis plc had a negative net margin of 198.87% and a negative return on equity of 22.58%.
Shares of Vernalis plc (VER) traded down 0.794% during midday trading on Tuesday, reaching GBX 15.625. 44,554 shares of the company were exchanged. Vernalis plc has a 52-week low of GBX 15.25 and a 52-week high of GBX 45.13. The company’s market capitalization is GBX 82.24 million. The firm’s 50 day moving average is GBX 16.94 and its 200-day moving average is GBX 19.79.
ILLEGAL ACTIVITY WARNING: “Vernalis plc (VER) Posts Earnings Results, Misses Estimates By $4.06 EPS” was published by Stock Observer and is owned by of Stock Observer. If you are viewing this piece on another website, it was copied illegally and republished in violation of United States and international trademark & copyright law. The original version of this piece can be accessed at https://www.thestockobserver.com/2017/09/12/vernalis-plc-ver-posts-earnings-results-misses-estimates-by-4-06-eps.html.
A number of brokerages recently commented on VER. Panmure Gordon reissued a “hold” rating and issued a GBX 31 ($0.40) price objective on shares of Vernalis plc in a research note on Monday, August 7th. Stifel Nicolaus lowered their price objective on shares of Vernalis plc from GBX 24 ($0.31) to GBX 21 ($0.27) and set a “hold” rating on the stock in a research note on Monday, August 7th. N+1 Singer reissued a “hold” rating and issued a GBX 28 ($0.36) price objective on shares of Vernalis plc in a research note on Monday, August 7th. Finally, RX Securities reissued a “buy” rating on shares of Vernalis plc in a research note on Monday, August 7th. Four equities research analysts have rated the stock with a hold rating and two have assigned a buy rating to the company. Vernalis plc presently has a consensus rating of “Hold” and a consensus target price of GBX 39.40 ($0.51).
Vernalis plc Company Profile
Vernalis plc is a commercial-stage pharmaceutical company. The Company is engaged in the research, development and commercialization of pharmaceutical products. The Company operates through two segments: Commercial, which covers all areas relating to the commercial sale of pharmaceutical products, the manufacture and distribution directly related to that activity, and Research and Development, which includes all activities related to the research and development of pharmaceutical products for a range of medical disorders.
Receive News & Ratings for Vernalis plc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Vernalis plc and related companies with MarketBeat.com's FREE daily email newsletter.